NCT06959095 - Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) | Biotech Hunter

Enrollment

981

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

August 20, 2029

Study Completion Date

August 20, 2029

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Depemokimab

Depemokimab as a sterile liquid formulation will be administered.

DRUG

Placebo

Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.

Trial Locations (15)

29732

RECRUITING

GSK Investigational Site, Rock Hill

33155

RECRUITING

GSK Investigational Site, Miami

33470

RECRUITING

GSK Investigational Site, Loxahatchee Groves

75110

RECRUITING

GSK Investigational Site, Corsicana

310000

RECRUITING

GSK Investigational Site, Hangzhou

410015

RECRUITING

GSK Investigational Site, Changsha

510150

RECRUITING

GSK Investigational Site, Guangzhou

511500

RECRUITING

GSK Investigational Site, Qingyuan

529000

RECRUITING

GSK Investigational Site, Jiangmen

610041

RECRUITING

GSK Investigational Site, Chengdu

643036

RECRUITING

GSK Investigational Site, Zigong

Unknown

RECRUITING

GSK Investigational Site, Chengdu

RECRUITING

GSK Investigational Site, Jiangxi

RECRUITING

GSK Investigational Site, Mianyang

140-8522

RECRUITING

GSK Investigational Site, Tokyo